13593-94-7 Usage
Uses
Used in Pharmaceutical Industry:
1,4-Dihydro-4-oxoquinoline-2-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be incorporated into the molecular structures of drugs, enhancing their therapeutic effects.
Used in Antimicrobial Applications:
In the field of antimicrobials, 1,4-Dihydro-4-oxoquinoline-2-carboxylic acid is utilized as an active ingredient for its antibacterial and antifungal properties, contributing to the development of drugs that combat resistant infections.
Used in Anti-inflammatory Applications:
1,4-Dihydro-4-oxoquinoline-2-carboxylic acid is employed as an anti-inflammatory agent, leveraging its potential to reduce inflammation and alleviate symptoms associated with inflammatory conditions.
Used in Anticancer Applications:
1,4-DIHYDRO-4-OXOQUINOLINE-2-CARBOXYLIC ACID is also used in oncology research and drug development as an anticancer agent, where it has been studied for its ability to inhibit the growth of cancer cells, offering a promising avenue for the treatment of various types of cancer.
Used in Organic Chemistry:
In the realm of organic chemistry, 1,4-Dihydro-4-oxoquinoline-2-carboxylic acid serves as a versatile building block for the synthesis of complex organic molecules, facilitating the creation of novel compounds with potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 13593-94-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,5,9 and 3 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 13593-94:
(7*1)+(6*3)+(5*5)+(4*9)+(3*3)+(2*9)+(1*4)=117
117 % 10 = 7
So 13593-94-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H7NO3/c12-9-5-8(10(13)14)11-7-4-2-1-3-6(7)9/h1-5H,(H,11,12)(H,13,14)
13593-94-7Relevant academic research and scientific papers
Protein–ligand interaction-guided discovery of novel VEGFR-2 inhibitors
Zhang, Yanmin,Zhang, Mingliang,Wang, Yuchen,Fan, Yuanrong,Chen, Xingye,Yang, Yan,Hua, Yi,Xie, Wuchen,Lu, Tao,Tang, Weifang,Chen, Yadong,Liu, Haichun
, p. 2559 - 2574 (2019/07/12)
As an effective target in abnormal angiogenesis-related tumor treatment, VEGFR-2 has small-molecule inhibitors of various scaffolds being approved for treating diseases such as renal carcinoma, non-small cell lung cancer, etc. However, endogenous and acqu
Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists
Borza, Istvan,Kolok, Sandor,Galgoczy, Kornel,Gere, Aniko,Horvath, Csilla,Farkas, Sandor,Greiner, Istvan,Domany, Gyoergy
, p. 406 - 409 (2007/10/03)
A novel series of kynurenic acid amides, ring-enlarged derivatives of indole-2-carboxamides, was prepared and identified as in vivo active NR2B subtype selective NMDA receptor antagonists. The synthesis and SAR studies are discussed.
Kynurenic acid derivatives inhibit the binding of nerve growth factor (NGF) to the low-affinity p75 NGF receptor
Jaen,Laborde,Bucsh,Caprathe,Sorenson,Fergus,Spiegel,Marks,Dickerson,Davis
, p. 4439 - 4445 (2007/10/03)
The ability of a series of substituted kynurenic acids, thienopyridinonecarboxylic acids, and related compounds to inhibit the binding of nerve growth factor (NGF) to the p75 NGF receptor (NGFR) was evaluated in a radioligand binding assay that utilized a
